Guggenheim Reiterates Buy on Teva Pharma (TEVA) Following AGN Deal
- Noble Energy (NBL) to Acquire Clayton Williams Energy (CWEI) for $2.7B in Cash and Stock
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Guggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) following the close of the company's AGN generics deal earlier this month. Later this month, TEVA will receive two decisions on the IPR challenge for Copaxone 40mg, about whether three patents have been invalidated and if a fourth will be considered for IPR.
Analyst Louise Chen commented, "After closing the AGN generics deal earlier this month, TEVA plans to provide investors with an overview of its generics business in September. We expect TEVA to give more details on the generics pipeline, integration, and synergy capture. We believe this could give the Street more confidence in TEVA's generics platform and its ability to mitigate risk from Copaxone. We do not expect generic competition until 2018+. Later this month, TEVA will receive two decisions on the IPR challenge for Copaxone 40mg, about whether three patents have been invalidated and if a fourth will be considered for IPR. However, the decision on the first three patents can be appealed, and even if IPR is instituted on the fourth, a decision may not come until 2018. There is also a parallel PIV process involving 5 companies in motion, and the trial starts 9/26. We expect a decision by 1Q17 when the 30-month stays expire, but if the decision is unfavorable, TEVA can appeal, which could take until 2018. A generic could still launch at-risk upon approval, but FDA has not approved any generics yet. We think MNTA (NC, $11.97) and NVS's (NC, $82.08) Sandoz could be approved, but note that they waited for the appellate decision before launching their generic 20mg last year."
Shares of Teva Pharma closed at $53.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) Receives Upgrades To Top Rating Recommendation From 3 Firms
- Wedbush Upgrades Tractor Supply Company (TSCO) to Outperform; Signs of Inflection
- UBS Reiterates Buy on Monster Beverage (MNST) After Meeting with Investors
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesLouise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!